Adaptive Radiation in Anal Cancer

• ClinicalTrials.gov Identifier: NCT05838391
• Recruitment Status: Recruiting
• First Posted: May 1, 2023
• Last Update Posted: July 13, 2023
• Sponsor: Columbia University
• Collaborator: Varian Medical Systems
• Information provided by (Responsible Party): Lisa A. Kachnic, Columbia University

Study Description

Brief Summary:

This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.

Condition or disease	Intervention/treatment	Phase
Anal Squamous Cell Carcinoma	Radiation: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery; Drug: Mitomycin-C; Drug: 5-Fluorouracil; Drug: Capecitabine	Not Applicable

Detailed Description:

The standard treatment for Human Papilloma Virus (HPV)-positive locally advanced anal cancer (described as a tumor that is greater than 4 cm in size, or with positive lymph nodes) is 54 Gy of radiation treatment to the anal canal and primary tumor planning total volume (PTV), 50.4-54 Gy to positive nodal PTV and 45 Gy to elective lymph node PTV with 5-fluorouracil (5-FU) and mitomycin-C chemotherapy administered at the same time as radiation in 30 fraction (treatments) delivery. During the six week course of radiotherapy, there is often a notable decrease in volume of the tumor (both primary and regional nodes), as early as one week into treatment, detected on weekly on-board Cone Beam Computed Tomography (CBCT), which is a scan done on the treatment machine while patients receive radiation to ensure that the tumor is being treated and normal tissue is not. However, CT simulation (a CT scan used to plan radiation treatment) and re-planning of the treatment to account for the tumor shrinkage are not routinely performed due to time, patient inconvenience and staffing resources. As such, daily adaptive radiation, which can generate a new CT-based plan using the anatomy of the day, may be a time efficient method to both plan and treat the patient.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma
• Actual Study Start Date: May 18, 2023
• Estimated Primary Completion Date: December 31, 2025
• Estimated Study Completion Date: December 31, 2028

Arms and Interventions

Arm

Intervention/treatment

Experimental: Chemotherapy and Adaptive Radiation Treatment Planning; Subjects will receive concurrent chemotherapy and radiation as part of their treatment for anal cancer. Subjects will receive standard of care 54 Gy of radiation, 5 days a week for 6 weeks. In addition, subjects will receive standard of care chemotherapy, with mitomycin C (10mg/meters squared IV on Day 1) and 5-Fluorouracil (1000mg/meters squared via IV on days 1-4 and 29-32) or capecitabine (825 mg/meters squared in two divided doses by mouth on days of radiotherapy).

Radiation: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery; Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.; Other Name: Adaptive RT Planning and Delivery; Drug: Mitomycin-C; As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.; Drug: 5-Fluorouracil; As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.; Other Name: 5-FU; Drug: Capecitabine; As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.; Other Name: Xeloda

Outcome Measures

Primary Outcome Measures :

1. Time to plan and deliver treatment fractions. [ Time Frame: Up to 6 weeks ]
   This is defined by the time the first cone beam computed tomography to the end of treatment delivery for each treatment.

Secondary Outcome Measures :

1. Acute Treatment Toxicity [ Time Frame: Up to 1 month post-treatment ]
   Toxicity of treatment will be analyzed using NCI-CTCAE v5.0.
2. Complete Clinical Response Rate [ Time Frame: 6 months following the completion of chemoradiation ]
   Complete response to treatment (CR) is defined as absence of detectable cancer.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically proven, invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal.
• American Joint Committee on Cancer (AJCC) 8th edition stage T2 > 4 cm, T3-4 or N1.
• Age ≥18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).
• Life expectancy of greater than 12 months.
• Patients must have normal organ and marrow function as defined below:
• leukocytes greater than or equal to 3,000/microliter
• absolute neutrophil count greater than or equal to 1,500/microliter
• platelets greater than or equal to 100,000/microliter
• total bilirubin within normal institutional limits
• Aspartate transaminase (AST)(SGOT)/Alanine transaminase (ALT)(SGPT) ≤ 2.5 × institutional upper limit of normal
• creatinine within normal institutional limits OR creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
• Females of childbearing potential and males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of study therapy. All pregnancies must be reported.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Prior or co-existing invasive malignancy (except non-melanomatous skin cancer) unless disease free ≥ 2 years.
• Prior chemotherapy or radiation for anal cancer.
• Patients who have undergone complete surgical resection.
• Presence of recurrent/metastatic disease.
• Prior allergic reaction to 5-Fluorouracil or mitomycin C.
• Artificial organ prosthetics, pacemakers or other implantable devices.
• Prior radiotherapy to the pelvis that would result in overlap of radiation therapy fields.
• Uncontrolled inter-current illness including but not limited to known history of HIV with cluster of differentiation 4 (CD4) count less than 200 or symptomatic cardiac disease.
• Women who are pregnant or lactating.

Contacts and Locations

Contacts

Contact: Mariamne Reyna; 646-317-4244; mo2213@cumc.columbia.edu

Locations

United States, New York

Columbia University Irving Medical Center; Recruiting

New York, New York, United States, 10032

Contact: Mariamne Reyna 646-317-4244 mo2213@cumc.columbia.edu

Principal Investigator: Lisa Kachnic, MD

Sub-Investigator: David Horowitz, MD

Sponsors and Collaborators

Columbia University

Varian Medical Systems

Investigators

• Principal Investigator: Lisa Kachnic, MD; Principal Investigator

More Information

• Responsible Party: Lisa A. Kachnic, Chu H. Chang Professor of Radiation Oncology; Chair, Department of Radiation Oncology, Columbia University
• ClinicalTrials.gov Identifier: NCT05838391
• Other Study ID Numbers: AAAU0074
• First Posted: May 1, 2023
• Last Update Posted: July 13, 2023
• Last Verified: July 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Lisa A. Kachnic, Columbia University:

Anal cancer; Adaptive radiation; Chemotherapy; Radiotherapy

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Squamous Cell; Anus Neoplasms; Neoplasms, Squamous Cell; Anus Diseases; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Rectal Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases; Capecitabine; Fluorouracil; Mitomycins; Mitomycin; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antibiotics, Antineoplastic